Isarna Therapeutics Raises €5.5 Million
News Apr 25, 2014
Isarna Therapeutics GmbH has announced that it has raised Euro 5.5 million ($7.6M) in equity from its current investors including AT NewTec, Global Asset Funds, and MIG Fonds.
The company has also announced that Elizabeth Czerepak has joined Isarna’s management team as Chief Financial Officer and Chief Business Officer to lead the company’s new office location in New York City.
"Isarna is committed to its leadership in TGF-β and we see Elizabeth’s addition to our management team, as well as our expansion into the U.S., as key strategic steps toward building our presence in the global biotech industry,” said Dr. Philippe Calais, Chief Executive Officer at Isarna Therapeutics. “We are grateful for the continued support and confidence from our investors as we work to create Isarna’s future.”
“Isarna’s goal of unlocking the power of TGF-β for cancer immunotherapy and as an innovative approach for treating ocular diseases and fibrosis is tremendously exciting and I am excited to join this impressive team and make an impact toward achieving success for the company,” added Ms. Czerepak.
Elizabeth Adkins Czerepak, MBA, brings to Isarna twenty-one years of pharmaceutical and biotechnology leadership experience and nine years as a venture capital investor at JP Morgan and Bear Stearns.
Ms. Czerepak has served in executive-level finance, licensing and corporate development positions, most recently as Chief Financial Officer and Principal Accounting Officer at Cancer Genetics, Inc. (CGIX), that she took public on NASDAQ and for which she raised three rounds of public financing totaling $69M.
Prior to CGI, Elizabeth worked at BASF Pharma (Knoll), Hoffmann-La Roche and Merck & Co.
Combining Different Malaria Vaccines Could Reduce Cases by 91%News
Using two experimental anti-malarial vaccines, which work in different ways, can greatly reduce the number of malaria infections in animal studies. Experimental vaccines, which independently achieve 48% and 68% reductions in malaria cases, can achieve 91% reduction when combined.
Targeting Epigenetic Proteins to Prevent Breast CancerNews
Researchers have discovered that epigenetic proteins promote the proliferation of mammary gland stem cells in response to the sex hormone progesterone. The study suggests that inhibiting these proteins with drugs could prevent the development of breast cancer in women at high risk of the disease.READ MORE
Targeting the Engine Room of the Cancer CellNews
Researchers at Columbia University Irving Medical Center (CUIMC) have developed a highly innovative computational framework that can support personalized cancer treatment by matching individual tumors with the drugs or drug combinations that are most likely to kill them.READ MORE